Plasmodia express two threonine-peptidase complexes during asexual development

Area of Science:

• Biochemistry
• Molecular Biology
• Parasitology

Background:

• Threonine-peptidases, like the proteasome, are crucial multi-subunit enzymes in eukaryotes, regulating protein turnover and cellular processes.
• Bacteria typically have ClpQ/hslV, a simpler T1-family peptidase, but Plasmodium falciparum uniquely possesses both proteasomal subunits and a ClpQ/hslV ortholog (PfhslV).
• The structure, expression, and function of these peptidase complexes in P. falciparum remain largely uncharacterized.

Purpose of the Study:

• To analyze the coding sequences and derived proteins of both proteasomal and PfhslV peptidase complexes in P. falciparum.
• To investigate the expression patterns and functional roles of these enzymes within the parasite.
• To identify potential drug targets for novel antimalarial therapies.

Main Methods:

• Bioinformatic analysis of coding sequences for proteasomal and PfhslV subunits.
• Expression analysis of PfhslV and proteasome during the P. falciparum cell cycle.
• Treatment of P. falciparum with the threonine-peptidase inhibitor epoxomicin to assess effects on parasite viability and protein ubiquitination.

Main Results:

• The proteasome is expressed throughout the P. falciparum cell cycle.
• PfhslV expression is restricted to schizonts and merozoites.
• Epoxomicin treatment inhibited proteasome activity, causing ubiquitinated protein accumulation and leading to parasite death.

Conclusions:

• This study provides the first functional characterization of Plasmodium threonine-peptidase complexes.
• The proteasome is essential for parasite survival and represents a promising target for antimalarial drug development.
• Epoxomicin demonstrates potential as a lead compound for a new class of antimalarial drugs targeting parasite proteases.